Hikma Pharmaceuticals Plc (LON:HIK) has received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is GBX 1,088.89 ($15.04).
A number of analysts have commented on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Hikma Pharmaceuticals in a report on Monday, January 15th. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($19.20) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 15th. Jefferies Group reissued an “underperform” rating and issued a GBX 895 ($12.37) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, January 17th. Morgan Stanley reissued an “equal weight” rating and issued a GBX 1,100 ($15.20) price objective on shares of Hikma Pharmaceuticals in a research note on Friday, December 1st. Finally, Barclays cut shares of Hikma Pharmaceuticals to an “underweight” rating and reduced their price objective for the stock from GBX 1,500 ($20.72) to GBX 800 ($11.05) in a research note on Thursday, March 1st.
Shares of Hikma Pharmaceuticals (LON HIK) traded down GBX 7.60 ($0.11) during mid-day trading on Friday, reaching GBX 872.40 ($12.05). 686,931 shares of the company’s stock were exchanged, compared to its average volume of 584,298. Hikma Pharmaceuticals has a twelve month low of GBX 814.20 ($11.25) and a twelve month high of GBX 2,346 ($32.41). The stock has a market capitalization of $2,100.00 and a PE ratio of 1,744.80.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Zolmax and is the property of of Zolmax. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://zolmax.com/investing/hikma-pharmaceuticals-plc-hik-receives-gbx-1088-89-consensus-target-price-from-brokerages/2007138.html.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.